Autopsy report · NCT04386278

OrthoPulse Gen 2 Initial Device Evaluation and Assessment of Clinical Effectiveness (CA)

“Study stopped because slow enrolment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 6 months before it stopped.
• 56 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Biolux Research Holdings, Inc.

Sponsor type

Industry

Conditions

Orthodontic Tooth Movement

Interventions

Intervention 1; Intervention 2; Intervention 3; Intervention 4; Intervention 5; Intervention 6

Participants

56

Sites

1

Countries

Canada

Trials that died the same way

• An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function
  “Study stopped due to lagging enrolment.” (89% match in meaning)
• UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome
  “Study stopped prematurely due to enrolment challenges.” (85% match in meaning)
• Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
  “Study stopped due to slow enrollment” (82% match in meaning)
• Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer
  “Study stopped due to low accrual.” (81% match in meaning)
• Hand Injected Ventriculography vs. Power Injected Left Ventriculography
  “Study was stopped due to low enrollment.” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.